| Literature DB >> 31167976 |
Laurent Bartolo1, Stéphanie Li Chung Tong1, Pascal Chappert1, Dominique Urbain1, Fanny Collaud2, Pasqualina Colella2, Isabelle Richard2, Giuseppe Ronzitti2, Jocelyne Demengeot3, David A Gross1, Federico Mingozzi2, Jean Davoust1.
Abstract
Immune responses to therapeutic transgenes are a potential hurdle to treat monogenic muscle disorders. These responses result from the neutralizing activity of transgene-specific B cells and cytotoxic T cells recruited upon gene transfer. We explored here how dual muscle-liver expression of a foreign transgene allows muscle transgene engraftment after adenoassociated viral vector delivery. We found in particular that induction of transgene-specific tolerance is imposed by concurrent muscle and liver targeting, resulting in the absence of CD8+ T cell responses to the transgene. This tolerance can be temporally decoupled, because transgene engraftment can be achieved in muscle weeks after liver transduction. Importantly, transgene-specific CD8+ T cell tolerance can be established despite preexisting immunity to the transgene. Whenever preexisting, transgene-specific CD4+ and CD8+ memory T cell responses are present, dual muscle-liver transduction turns polyclonal, transgene-specific CD8+ T cells into typically exhausted T cells with high programmed cell death 1 (PD-1) expression and lack of IFN-γ production. Our results demonstrate that successful transduction of muscle tissue can be achieved through liver-mediated control of humoral and cytotoxic T cell responses, even in the presence of preexisting immunity to the muscle-associated transgene.Entities:
Keywords: Adaptive immunity; Gene therapy; Immunology; T cells
Year: 2019 PMID: 31167976 PMCID: PMC6629094 DOI: 10.1172/jci.insight.127008
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708